Full Coverage

Favrille pulls plug on lead drug candidate Specifid

marketwatch.com
May 27, 2008
        
Story Timeline:  191 days

BOSTON (MarketWatch) -- Biotech group Favrille Inc. said early Tuesday that it was discontinuing development of its lead drug candidate Specifid due to disappointing Phase III clinical results. Favrille had been testing Specifid for the treatment of non-Hodgkin's lymphoma in conjunction with the... [read full story]                    

Add Comment
Latest article on this story:

Favrille's lymphoma drug fails end point

 pharmaceutical-business-review.com May 28, 2008
First article on this story:

Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with...

 prnewswire.com May 27, 2008
Selected publications with coverage of this story:
pharmaceutical-business-review.com medicalnewstoday.com yahoo.com emaxhealth.com ibtimes.com forbes.com prnewswire.com marketwatch.com signonsandiego.com earthtimes.org drugs.com tmcnet.com
RELATED
Found 18 documents:

Favrille's lymphoma drug fails end point

pharmaceutical-business-review.com
May 28, 2008
        

Favrille has announced results from the company's Phase III registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma. Analysis of time to progression (TTP), the primary endpoint in the trial, failed to show a statistically significant improvement...

Drug trial by Favrille has shown no benefit

signonsandiego.com
May 28, 2008
        

Failure of Specifid puts company future on line Shares of the San Diego biotechnology company Favrille nose-dived yesterday after the company said its drug aimed at triggering the immune system to fight non-Hodgkin's lymphoma failed to show any benefit in a pivotal, late-stage clinical trial. The...

Favrille Inc. shares Slump near 90% as it discontinues Specifid Cancer Drug

ibtimes.com
May 27, 2008
        

NEW YORK - Biopharmaceutical group Favrille Inc. shares slumped near 90 percent on Tuesday after the company said it will stop the development of its lead cancer drug, Specifid, as it failed to meet a strategic goal in a late stage trial. Favrille said the study of Specifid which was a potential...

Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with...

drugs.com
May 27, 2008
        

Results Fail to Show Statistically Significant Improvement in Primary Endpoint, Time to Progression, Compared to Control SAN DIEGO, May 27, 2008 /PRNewswire-FirstCall/ -- Analysis of time to progression (TTP), the primary endpoint in the trial, failed to show a statistically significant...

Favrille Ends Trials With Nothing Left (at Forbes.com)

yahoo.com
May 27, 2008
        

Cancer is the new hot space for pharmaceutical companies, but competition creates losers as well as winners. Big Pharma companies like Pfizer are bulking up their cancer research and small biotechs are diving into the area head-first, resulting in a rocky time for the smaller firms, which may...

Favrille Ends Trials With Nothing Left

forbes.com
May 27, 2008
        

Cancer is the new hot space for pharmaceutical companies, but competition creates losers as well as winners. Big Pharma companies like Pfizer are bulking up their cancer research and small biotechs are diving into the area head-first, resulting in a rocky time for the smaller firms, which may...

                   

Favrille Sinks on Phase III Failure of Lead Cancer Drug

tmcnet.com
May 27, 2008
        

Most of Favrille Inc.'s market value vanished Tuesday after the firm said it would cease development of its active immunotherapy Specifid, which missed its primary endpoint in a pivotal Phase III study in non-Hodgkin's lymphoma (NHL). Specifid in combination with Bayer Healthcare Pharmaceutical...

Favrille's Phase 3 Data Call scheduled for 8:30 am ET today (CCBN)

yahoo.com
May 27, 2008
        

Favrille, Inc., a biopharmaceutical company, engages in the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. Its principal product candidate includes Specifid, a following rituxan induction therapy that is in phase III trial...

UPDATE - Favrille stops lead cancer drug trials; shares sink (at Reuters)

yahoo.com
May 27, 2008
        

By Jennifer Robin Raj BANGALORE, May 27 (Reuters) - Favrille Inc (FVRL.O: ) said it will end development of its lead experimental cancer drug, Specifid, as it failed to meet the main goal in a late-stage trial, wiping out about 86 percent of the company's market value. Brean Murray Carret & Co...

Favrille Announces Positive Results From Specifid Trial

emaxhealth.com
May 27, 2008
        

Favrille announced results from Phase 3 registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). Analysis of time to progression (TTP), the primary endpoint in the trial, failed to show a statistically significant improvement in the...

1 2 next

               

Related categories

Favrille